The UC Davis Cancer Center, the only NCI-designated cancer center in the Central Valley of California, is the advanced cancer care provider for a population of five million, the only significance point of access to early phase cancer clinical trials in its Northern California region, and together with its collaborator, the Lawrence Livermore National Laboratory [LLNL], the region's principal cancer research organization. Since its founding thirteen years ago, the UC Davis Cancer Center has provided increasingly progressive leadership to, organization of, and support for cancer investigation. In the first sections, we recapitulate briefly the milestones leading up to NCI designation (July 1, 2002). In subsequent sections, we focus on decisions, achievements, and directions characterizing the center's first two years of its Cancer Center Support Grant [CCSG]. In concluding sections, we focus on program and organizational accomplishments, future direction, and geography.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA093373-08S3
Application #
7931101
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
2009-09-30
Project End
2011-09-29
Budget Start
2009-09-30
Budget End
2011-09-29
Support Year
8
Fiscal Year
2009
Total Cost
$1,450,579
Indirect Cost
Name
University of California Davis
Department
Urology
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182
Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331
Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162
Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529
Jerant, Anthony; Fenton, Joshua J; Kravitz, Richard L et al. (2018) Association of Clinician Denial of Patient Requests With Patient Satisfaction. JAMA Intern Med 178:85-91
Tepper, Clifford G; Dang, Julie H T; Stewart, Susan L et al. (2018) High frequency of the PNPLA3 rs738409 [G] single-nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease. Cancer 124 Suppl 7:1583-1589
Besprozvannaya, Marina; Dickson, Eamonn; Li, Hao et al. (2018) GRAM domain proteins specialize functionally distinct ER-PM contact sites in human cells. Elife 7:
Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2018) A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol 180:445-448
Matsumoto, Collin; Jiang, Yan; Emathinger, Jacqueline et al. (2018) Short Telomeres Induce p53 and Autophagy and Modulate Age-Associated Changes in Cardiac Progenitor Cell Fate. Stem Cells 36:868-880
Turner, David C; Kondic, Anna G; Anderson, Keaven M et al. (2018) Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clin Cancer Res 24:5841-5849

Showing the most recent 10 out of 836 publications